Chn-1/chip-antagonists for the treatment of muscular diseases

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 45/00 (2006.01) A01K 67/027 (2006.01) A61K 39/395 (2006.01) A61P 21/00 (2006.01) C12N 15/11 (2006.01) G01N 33/50 (2006.01)

Patent

CA 2575683

The present invention relates to a pharmaceutical composition comprising an inhibitor/negative regulator/antagonist of the mammalian ortholog of Caenorhabditis elegans CHN-1 and/or of the human CHIP (carboxyl-terminus of Hsc70 interacting protein). Furthermore, the use of said inhibitor/negative regulator/antagonist in medical and pharmaceutical settings is described. In addition, screening methods and tools for the identification of CHIP/CHN-1 inhibitors/antagonists are provided.

La présente invention concerne une composition pharmaceutique contenant un régulateur/antagoniste inhibiteur/négatif de l'orthologue mammalien de Caenorhabditis elegans CHN-1 et/ou de CHIP humain (terminaison carboxyle de la protéine à interaction Hsc70). En outre, cette invention a pour objet l'utilisation du régulateur/antagoniste inhibiteur/négatif dans des préparations médicales et pharmaceutiques, ainsi que des méthodes de criblage et des outils destinés à l'identification d'inhibiteurs/antagonistes CHIP/CHN-1.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Chn-1/chip-antagonists for the treatment of muscular diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chn-1/chip-antagonists for the treatment of muscular diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chn-1/chip-antagonists for the treatment of muscular diseases will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1930346

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.